23.46
0.03 (0.13%)
| Previous Close | 23.43 |
| Open | 23.44 |
| Volume | 546,477 |
| Avg. Volume (3M) | 312,012 |
| Market Cap | 151,602,736 |
| Price / Earnings (Forward) | 56.50 |
| Price / Sales | 1.48 |
| Price / Book | 2.01 |
| 52 Weeks Range | |
| Earnings Date | 10 Aug 2026 |
| Profit Margin | -25.72% |
| Operating Margin (TTM) | -48.87% |
| Diluted EPS (TTM) | -0.320 |
| Quarterly Revenue Growth (YOY) | -18.40% |
| Total Debt/Equity (MRQ) | 37.12% |
| Current Ratio (MRQ) | 1.66 |
| Operating Cash Flow (TTM) | 6.36 M |
| Levered Free Cash Flow (TTM) | 16.48 M |
| Return on Assets (TTM) | -6.60% |
| Return on Equity (TTM) | -25.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Assertio Holdings, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | NA |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | -0.50 |
|
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 2.52% |
| % Held by Institutions | 26.92% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |